Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Elan A. Cohen
Observed names:
E.A. Cohen,
Elan A Cohen,
Elan Cohen
Institution:
Hassman Research Institute
Observed institutions:
Hassman Research Institute,
Vibrant Emotional Health,
National Institute of Mental Health,
University of Pennsylvania
ORCID:
0009-0009-6252-9130
Observed ORCID:
0009-0009-6252-9130
OpenAlex ID:
A5073428828
College Students’ Reasons for Not Drinking and Not Playing Drinking Games
2004
·
Thomas J. Johnson
, Elan A. Cohen
·
Substance Use & Misuse
·
41
Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders
2020
·
Elan A. Cohen
, Howard H. Hassman
, et al.
·
Neuropsychopharmacology
·
21
PDF
Phase 3b Multicenter, Prospective, Open-label Trial to Evaluate the Effects of a Digital Medicine System on Inpatient Psychiatric Hospitalization Rates for Adults With Schizophrenia
2022
·
Elan A. Cohen
, Taisa Skubiak
, et al.
·
The Journal of Clinical Psychiatry
·
17
PDF
The Dimensionality of Family Differentiation and the Prediction of Adolescent Internalized Distress
2003
·
Elan A. Cohen
, Michael W. Vasey
, et al.
·
Journal of Family Issues
·
16
Increases in Demand for Crisis and Other Suicide Prevention Services After a Celebrity Suicide
2019
·
Rajeev Ramchand
, Elan Cohen
, et al.
·
Psychiatric Services
·
13
Healthcare Provider Engagement with a Novel Dashboard for Tracking Medication Ingestion: Impact on Treatment Decisions and Clinical Assessments for Adults with Schizophrenia
2022
·
Jeffrey M Cochran
, Hui Fang
, et al.
·
Neuropsychiatric Disease and Treatment
·
8
PDF
Safety and Efficacy of the NMDA‐2b‐Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder
2025
·
Roger S. McIntyre
, Gerard Sanacora
, et al.
·
Clinical Pharmacology & Therapeutics
·
3
PDF
Efficacy, Tolerability, and Safety of TRPC4/5 Inhibitor BI 1358894 in Patients With Major Depressive Disorder and Inadequate Response to Antidepressants: A Phase 2 Randomized, Placebo-Controlled, Parallel Group, Dose-Ranging Trial
2025
·
Richard C. Shelton
, Diego A. Pizzagalli
, et al.
·
The Journal of Clinical Psychiatry
·
2
Baseline Mismatch Negativity Amplitude Predicts Direction and Magnitude of Ketamine Effect in Healthy Volunteers: A Disordinal Effect
2026
·
Marco Cecchi
, Jason Johannesen
, et al.
·
Biological Psychiatry
·
1
PDF
1922 – The Evaluation Of Negative Symptoms By Videoconferencing In a Clinical Trial
2013
·
J.B.W. Williams
, D. Popp
, et al.
·
European Psychiatry
·
1
NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trials
2026
·
Elan A. Cohen
, Gerard Sanacora
, et al.
·
Neuropsychopharmacology
PDF
S35. the Placebo Conundrum: Mitigating the Response at the Site Level
2020
·
Howard Hassman
, Elan Cohen
, et al.
·
Schizophrenia Bulletin
PDF
Reasons for Not Drinking Scale
2004
·
Thomas J. Johnson
, Elan A. Cohen
·
PsycTESTS Dataset
Show more works
View as search
Works count:
13
Citation count:
123
H-index:
6
I10-index:
5
Year
Topic
Type